L. Hannah Alison's most recent trade in Neogenomics Inc. was a trade of 23,077 Restricted Stock Unit done . Disclosure was reported to the exchange on June 1, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Neogenomics Inc. | Hannah L. Alison | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2025 | 23,077 | 23,077 | - | - | Restricted Stock Unit | |
| Neogenomics Inc. | Alison L. Hannah | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2025 | 16,107 | 16,107 | - | - | Stock Option (Right to Buy) | |
| Neogenomics Inc. | Alison L. Hannah | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2025 | 12,254 | 131,023 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc. | L. Alison Hannah | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2025 | 12,254 | 131,023 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc. | L. Hannah Alison | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2025 | 12,254 | 0 | - | - | Restricted Stock Unit | |
| Rigel Pharmaceuticals | Alison L. Hannah | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2025 | 3,000 | 3,000 | - | - | Stock Option (Right to Buy) | |
| Rigel Pharmaceuticals | Alison L. Hannah | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2025 | 2,500 | 10,625 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc. | Alison L. Hannah | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2024 | 11,336 | 118,769 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc. | Alison L. Hannah | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2024 | 11,336 | 0 | - | - | Restricted Stock Unit | |
| Neogenomics Inc. | Alison L. Hannah | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2024 | 12,254 | 12,254 | - | - | Restricted Stock Unit | |
| Neogenomics Inc. | Alison L. Hannah | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2024 | 8,672 | 8,672 | - | - | Stock Option (Right to Buy) | |
| Rigel Pharmaceuticals | Alison L. Hannah | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2024 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Rigel Pharmaceuticals | Alison L. Hannah | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2024 | 25,000 | 81,250 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc. | Alison L. Hannah | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2023 | 11,336 | 11,336 | - | - | Restricted Stock Unit | |
| Neogenomics Inc. | Alison L. Hannah | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2023 | 8,353 | 8,353 | - | - | Stock Option (Right to Buy) | |
| Rigel Pharmaceuticals | Alison L. Hannah | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2023 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Rigel Pharmaceuticals | Alison L. Hannah | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2023 | 25,000 | 56,250 (0%) | 0% | 0 | Common Stock | |
| CytomX Therapeutics Inc | Alison L. Hannah | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jul 2022 | 15,000 | 37,500 (0%) | 0% | 0 | Common Stock | |
| CytomX Therapeutics Inc | Alison L. Hannah | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 1.42 per share. | 19 Jul 2022 | 5,602 | 31,898 (0%) | 0% | 1.4 | 7,965 | Common Stock |
| Neogenomics Inc. | Alison L. Hannah | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 15,556 | 107,433 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc. | Alison L. Hannah | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 13,882 | 13,882 | - | - | Stock Option (Right to Buy) | |
| Rigel Pharmaceuticals | Alison L. Hannah | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2022 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Rigel Pharmaceuticals | Alison L. Hannah | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2022 | 25,000 | 31,250 (0%) | 0% | 0 | Common Stock | |
| CytomX Therapeutics Inc | Alison L. Hannah | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2022 | 135,000 | 135,000 | - | - | Stock Option (Right to Buy) | |
| CytomX Therapeutics Inc | Alison L. Hannah | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2022 | 22,500 | 22,500 (0%) | 0% | 0 | Common Stock | |
| CytomX Therapeutics Inc | Alison L. Hannah | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Oct 2021 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| CytomX Therapeutics Inc | Alison L. Hannah | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Oct 2021 | 30,000 | 30,000 | - | - | Performance Stock Units (PSUs) | |
| CytomX Therapeutics Inc | Alison L. Hannah | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2021 | 175,000 | 175,000 | - | - | Stock Option (right to buy) |